Drugs / ML261
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07488923 | Jun 2026 → Mar 2028 expected | digestive system neuroendocrine neoplasm, prostate neuroendocrine neoplasm, small cell lung carcinoma | Moonlight Bio, Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ML261 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07488923 ↗ |
| Modality | Cell therapy | “anti-DLL3 CAR T cell therapy” NCT07488923 ↗ |
| Target | DLL3 | “anti-DLL3 CAR T cell therapy” NCT07488923 ↗ |